Comparing the current results to its competitors, Esperion Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 23.25 % year on year. The sales growth was above Esperion Therapeutics Inc 's competitors' average revenue growth of 12.42 %, achieved in the same quarter.
Esperion Therapeutics Inc , slower than the average decrease reported by the company's competitors of -31.77 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -31.77 %
Esperion Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive industry marked by rapid technological change. Competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies, and research institutions. Key competitive factors include efficacy, safety and tolerability profiles, reliability, dosing convenience, price, and reimbursement. The market for cholesterol-regulating therapies is particularly large and competitive. The company's product candidates, whether as monotherapies or combination therapies, face competition from existing or potential competitors with substantially greater financial and technological resources.
August 29, 2025
In a significant advancement for the field of dyslipidemia management, Esperion Therapeutics Inc. announced that its drug, Bempedoic Acid, has received a Level 1a recommendation in the updated European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) guidelines. This recommendation underscores the impressive clinical data supporting the drug s efficacy and safety, positioning it as a critical option for patients struggling with dyslipidemia. The endorsement from leading cardiology organizations highlights the potential of Bempedoic Acid to change clinical practice and offers hope for improved lipid management in patients at high cardiovascular risk.Alongside this clinical recognition, E...
December 12, 2024
Esperion Therapeutics: Innovative Growth and Strategic Partnerships In a rapidly evolving pharmaceutical landscape, Esperion Therapeutics Inc. has stood out as a noteworthy success story in recent times. With a burgeoning interest in innovative solutions for cholesterol management, the company has successfully aligned itself with strategic global partnerships and achieved admirable financial growth amidst challenging industry dynamics. NEXLETOL and NEXLIZET: Expanding the Market Horizon Esperion s collaboration with Neopharm to commercialize two of its flagship products, NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe), in Israel marks a significant milestone in expandi...
January 4, 2024
Esperion Therapeutics and Daiichi Sankyo Europe: Strengthening Collaboration and Resolving Commercial Disputes for Future GrowthEsperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europa GmbH (DSE) recently announced a significant expansion of their collaboration, amounting to $125 million. This collaboration includes a mutual resolution of their commercial dispute and other strategic changes aimed at enhancing long-term value for their products. These developments mark an important milestone for both companies and have implications for the broader pharmaceutical industry.Resolving the Dispute: A Win-Win SituationOne of the pivotal aspects of this collaboration is the mutual resolution of the comme...
January 3, 2024
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationIn a landmark agreement, Esperion and Daiichi Sankyo Europe have revealed a substantial amendment to their existing collaboration, along with the resolution of a long-standing litigation. The amendment entails a near-term payment of $100 million to Esperion, followed by an additional $25 million in the calendar quarter after the European Medicines Agency (EMA) delivers its decision on Type II(a) variation approval for NILEMDO (bempedoic acid) Tablet and NUSTENDI (bempedoic acid and ezetimibe) Tablet.This groundbreaking partnership amendment marks a significant milestone for bot...
Publicly Traded Peers of Esperion Therapeutics Inc
Adagene Inc Share Performance
-2.72%
Over The Past 5 Days
Adagene Inc
Profile
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Sources:
Esperion Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Esperion Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
